Age Labs provides custom biomarker development, data analysis and comprehensive reports on epigenetic drug effects for use in clinical trials. Our customers asks for the development of diagnostic tests for early detection, patient selection or drug response - or to improve their understanding of drug effects or mechanisms of action.
Age Labs provides extensive reports for use in clinical trials on disease phenotypes and drug effects.
By measuring epigenetic status of immune cells at the start and end of an intervention, we offer valuable information on how an intervention has changed the immune response and its relation to disease risk.
We measure DNA methylation in immune cells using Illumina microarrays, analyzing 850,000 CpG sites, covering 99% of the RefSeq genes.
Using state-of-the-art machine learning we perform in-depth analysis of your data to identify correlations, thus improving the understanding of both disease mechanisms and drug effects.
The analyses result in a comprehensive report for use in clinical trials.
Age Labs has developed EPIPHANY, a machine learning-based biomarker discovery platform. Using EPIPHANY, we can measure the regulatory domains of 99% of the human genome to create rich epigenetic profiles. These epigenetic profiles enable us to quantify how genes are activated ahead of—and in response to—disease. We have built a unique database of such profiles coupled with extensive health data, from unique and extensive biobanks.
The EPIPHANY platform enables rapid and accurate biomarker development and is available through collaboration with us.